Selvita S.A.
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more
Selvita S.A. - Asset Resilience Ratio
Selvita S.A. (SLV) has an Asset Resilience Ratio of 0.06% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Selvita S.A.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Selvita S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł367.00K | 0.06% |
| Total Liquid Assets | zł367.00K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Selvita S.A. maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Selvita S.A. Industry Peers by Asset Resilience Ratio
Compare Selvita S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Selvita S.A. (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Selvita S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.05% | zł311.00K | zł636.26 Million | -0.30pp |
| 2022-12-31 | 0.35% | zł2.02 Million | zł584.91 Million | -2.53pp |
| 2021-12-31 | 2.88% | zł13.43 Million | zł466.59 Million | -1.76pp |
| 2020-12-31 | 4.64% | zł10.15 Million | zł218.80 Million | +4.52pp |
| 2018-12-31 | 0.12% | zł89.37K | zł72.58 Million | -0.07pp |
| 2017-12-31 | 0.19% | zł92.69K | zł47.94 Million | +0.13pp |
| 2016-12-31 | 0.07% | zł60.00K | zł89.12 Million | -- |